945347-61-5 Usage
Uses
Used in Pharmaceutical Industry:
2-[(2-Methoxyethyl)amino]nicotinonitrile is used as a psychoactive drug for its sedative and anxiolytic effects, making it a potential candidate for the treatment of anxiety disorders and sleep disorders. Its benzodiazepine-like properties allow it to modulate the central nervous system, providing relief from symptoms associated with these conditions.
Used in Recreational Purposes:
2-[(2-Methoxyethyl)amino]nicotinonitrile is used as a designer drug for recreational purposes due to its psychoactive effects. Its ability to induce sedation and reduce anxiety makes it a popular choice among individuals seeking these effects. However, the use of Meclonazepam for recreational purposes poses significant health risks and is not recommended.
Check Digit Verification of cas no
The CAS Registry Mumber 945347-61-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,5,3,4 and 7 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 945347-61:
(8*9)+(7*4)+(6*5)+(5*3)+(4*4)+(3*7)+(2*6)+(1*1)=195
195 % 10 = 5
So 945347-61-5 is a valid CAS Registry Number.
945347-61-5Relevant academic research and scientific papers
PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN
-
Page/Page column 38, (2012/01/13)
Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, and Q are defined herein.
Prokineticin 1 receptor antagonists
-
Page/Page column 38, (2008/12/04)
The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.
PROKINETICIN 2 RECEPTOR ANTAGONISTS
-
Page/Page column 105, (2010/11/28)
The present invention relates to certain novel compounds of Formula (I): and methods for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders.
